SINGAPORE - AstraZeneca will invest US$1.5 billion in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs), the biopharmaceutical giant announced Monday. AstraZeneca aims ...
CEO Pascal Soriot is working to ensure AstraZeneca can independently supply drugs to major markets as the US pushes to reduce ...
British pharmaceutical company AstraZeneca announced on May 20 its intention to build a 1.5 billion USD facility in Singapore ...
SINGAPORE: Pharmaceutical company AstraZeneca announced it would build a cancer treatment facility in Singapore. The US$1.5 ...
British pharmaceutical company AstraZeneca announced on May 20 its intention to build a 1.5 billion USD billion facility in ...
AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of ...
AstraZeneca says it will invest 1.5 billion U.S. dollars in building a manufacturing facility in Singapore for antibody drug conjugates (ADCs). AstraZeneca says it will invest 1.5 billion U.S. dollars ...
AstraZeneca intends to build a $1.5 billion next-generation manufacturing facility in Singapore to produce ADCs for cancer ...
Global biopharmaceutical company AstraZeneca intends to build a US$1.5bil manufacturing facility in Singapore, the company ...